AdvanSix Inc (ASIX)

AdvanSix Inc. announced a new $425 million senior secured credit facility with Citizens Bank, N.A., refinancing its previous credit agreement. This facility includes a $275 million revolving credit and a $150 million term loan, both maturing on August 14, 2031. The funds will be used to repay prior obligations, cover expenses, and for general corporate purposes, subject to specific financial covenants.

AdvanSix (ASIX) has completed a refinancing agreement, securing a new Credit Agreement that includes a $275 million senior secured revolving credit facility and a $150 million senior secured term loan, both maturing on August 14, 2031. Citizens Bank is the administrative agent for these new facilities. This new agreement replaces the company's previous 2021 facility with Truist, aiming to enhance liquidity and provide general corporate support.

AdvanSix Inc. has completed a refinancing of its existing credit facilities by entering into a new Credit Agreement. This new agreement provides for a $275 million senior secured revolving credit facility and a $150 million senior secured term loan facility, both maturing on August 14, 2031. The proceeds from these new facilities were primarily used to refinance existing obligations and for general corporate purposes, with approximately $17 million cash on hand after the initial borrowing.

American Century Investment Management, Inc., along with American Century Companies, Inc. and the Stowers Institute for Medical Research, has reported a 5.1% beneficial ownership stake in AdvanSix Inc. (ASIX) common stock. This Schedule 13G filing indicates that the group collectively holds 1,363,346 shares with sole voting and dispositive power. The filing specifies that no single client advised by American Century Investment Management, Inc. holds more than 5% of AdvanSix's common stock.

AdvanSix (NYSE:ASIX) is forecast to grow earnings and revenue significantly, with an expected EPS growth of 196.3% per annum, despite recent price target decreases and past earnings declines. The company faces short-term headwinds, including a 90% net income drop in Q2 2026, leading to a "Hold" rating from one analyst due to unattractive risk/reward and macro risks. However, there are also optimistic outlooks pointing to potential turnarounds driven by cost discipline, nutrient market demand, and new finance leadership.